Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors
The Journal of Clinical Psychiatry · 2023
DOI: 10.4088/jcp.22m14734 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Psychiatry, 2023. Verfasst von Justine Benevent und 7 weiteren Autor:innen. Beteiligte Einrichtung: REGARDs Network, Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire de Toulouse, CERPOP INSERM UMR 1295 - SPHERE team, Faculté de M…. Hauptthemen laut MEDLINE: Serotonin and Noradrenaline Reuptake Inhibitors, Hypertension, Pregnancy-Induced. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Among antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs) are particularly expected to increase the risk of hypertensive disorders of pregnancy (HDP) with regard to their biological mechanism. We aimed to evaluate the association between prenatal exposure to SNRI and HDP.
Methods
In EFEMERIS, a French database including pregnant women covered by the French Health Insurance System of Haute-Garonne (2004-2019), we compared the incidence of HDP among women exposed to SNRI monotherapy during the first trimester of pregnancy to the incidence among 2 control groups: (1) women exposed to selective serotonin reuptake inhibitor (SSRI) monotherapy during the first trimester and (2) women not exposed to antidepressants during pregnancy. We conducted crude and also multivariate logistic regressions.
Results
Of the 156,133 pregnancies, 143,391 were included in the study population, including 210 (0.1%) in the SNRI group, 1,316 (0.9%) in the SSRI group, and 141,865 (98.9%) in the unexposed group. After adjustment for depression severity and other mental conditions, the risk of HDP was significantly higher among women exposed to SNRIs (n = 20; 9.5%) compared to women exposed to SSRIs (n = 72; 5.5%; adjusted odds ratio [aOR] [95% CI] = 2.32 [1.28-4.20]) and to unexposed women (n = 6,224; 4.4%; aOR [95% CI] = 1.89 [1.13-3.18]).
Conclusion
This study indicated an increased risk of HDP in women treated with SNRIs versus women treated with SSRIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- REGARDs Network, Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire de Toulouse, CERPOP INSERM UMR 1295 - SPHERE team, Faculté de Médecine Université de Toulouse, Toulouse, France.
- Corresponding Author: Justine Benevent, PharmD, PhD, Faculté de Médecine, 37 allées Jules Guesde, 31000, Toulouse, France (justine.benevent@univ-tlse3.fr).
- Université Paris Cité, INSERM UMR1266, Institute of Psychiatry and Neurosciences, Team 1, Paris, France (Tebeka); Department of Psychiatry, AP-HP, Louis Mourier Hospital, Colombes, France.
Zitieren
APA
Benevent, J., Araujo, M., Karki, S., Delarue-Hurault, C., Waser, J., Lacroix, I., Tebeka, S., & Damase-Michel, C. (2023). Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.22m14734
Vancouver
Benevent J, Araujo M, Karki S, Delarue-Hurault C, Waser J, Lacroix I, et al. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors. The Journal of Clinical Psychiatry. 2023. doi:10.4088/jcp.22m14734
BibTeX
@article{Benevent2023,
author = {Benevent, Justine and Araujo, Mélanie and Karki, Sudip and Delarue-Hurault, Caroline and Waser, Julie and Lacroix, Isabelle and Tebeka, Sarah and Damase-Michel, Christine},
title = {Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors},
journal = {The Journal of Clinical Psychiatry},
year = {2023},
doi = {10.4088/jcp.22m14734}
}
EUVIMED